Thomas M. Yankee, Pharm.D., Ph.D.

Associate Professor
Director, Inflammation & Immunity Module (I2, CORE 810)
Microbiology, Molecular Genetics and Immunology

Pharm.D., University of Illinois at Chicago, 1995
Ph.D., Purdue University, West Lafayette, Indiana, 1999


Publications: Click here

lab website

Project 1:

T cell development and leukemogenesis: T cell homeostasis is critical for maintaining the balance between immune competency, autoimmunity, and malignancy.  A key element in T cell homeostasis lies in the ability of the thymus to provide a continuous source of naïve T cells throughout one's life.  Using murine and human models, we are defining the stages of T cell development and determining the events that occur at each stage.  We focus on the signaling events and transcription factors that drive T cell development because aberrant transcriptional regulation can lead to T cell acute lymphoblastic leukemia, a heterologous set of diseases that can arise from nearly any stage of T cell development.  Our goal is to determine how normal human thymocytes transform into leukemic cells.

 Project 2:

Anti-cancer immunotherapy: One function of T cells is to target and destroy tumor cells.  We are using chimeric antigen receptor (CAR) technology to modify T cells in a manner that make them potent tumor killers.  CAR technology involves the fusion of a synthetic molecule that can bind tumor antigens with endogenous signaling proteins that induce the activation of the T cells.  The chimeric receptor can be delivered into patient's T cells, which are then reinfused into the patient where they bind to tumor cells and destroy the tumor.  We are developing technology with the goal of dramatically improving the efficacy of the CARs.

 Project 3:

Immunomodulatory therapy for use in solid organ transplantation and autoimmunity: When T cells attack allografts, allograft rejection can result.  Likewise, when T cells attack our own tissues, an autoimmune disease can be the result.  We are using T cell-based immunotherapeutic approaches to suppress the immune system to protect allografts and other tissues.

Selected Publications

  • Xiong J., Parker B.L., and Yankee T.M. (2014) The combined loss of Gads and CD127 reveals a novel function of Gads prior to TCRb expression. (Immunol. Res.,in press).
  • Xiong J., Parker B.L., and Yankee T.M. (2013) IL-7 supports survival of TCRβ-expressing CD4(-) CD8(-) double negative thymocytes. Immunol. 138: 382-91
  • Zhang E.Y., Parker B.L., Xiong, J., Chen, A.Y., Qiu, J., Ma, X., and Yankee, T.M. (2011) Depletion and recovery of lymphoid subsets following morphine administration. Brit. J. Pharmocol., 164: 1829-44.
  • Zhang E.Y., Parker B.L., and Yankee T.M. (2011) Gads regulates the kinetics of CD8+ T cell activation and proliferation. J. Immunol. 186: 4579-89.
  • Xiong J., Armato M.A., Yankee TM. (2011) Immature single-positive CD8+ thymocytes represent the transition from Notch-dependent to Notch-independent T-cell development. Int. Immunol., 23: 55-64.
  • Dalheimer, S.D., Zeng, L., Draves, K.E., Jiwa, N.N., Parrish, T.D., Clark, E.A., and Yankee, T.M. (2009) Gads-deficient thymocytes are blocked at the transitional single positive CD4+ stage. Eur. J. Immunol., 39: 1395.
  • Zeng, L., Dalheimer, S.L., and Yankee, T.M. (2007) Gads-/- Mice Reveal Functionally Distinct Subsets of TCRbeta+ CD4-CD8- Double-Negative Thymocytes. J. Immunol. 179: 1013-21.
Last modified: Oct 29, 2014

Thomas M. Yankee, Pharm.D., Ph.D.

Contact

Thomas M. Yankee, Pharm.D., Ph.D.
Associate Professor
Director, Inflammation & Immunity Module (I2, CORE 810)

Office: 3004 Hixon
Lab: 3005 Wahl Hall West

P: (913) 588-2507
(913) 588-0886
tyankee@kumc.edu

ID=x2735